| General Information | |
|---|---|
| ZINC ID | ZINC000299836131 |
| Molecular Weight (Da) | 391 |
| SMILES | O=C(NC1(c2ccccc2)CC1)c1nn(-c2ccc(F)cc2F)c2c1C[C@H]1C[C@@H]21 |
| Molecular Formula | C23F2N3O1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 105.426 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 29 |
| LogP | 4.513 |
| Activity (Ki) in nM | 1.413 |
| Polar Surface Area (PSA) | 46.92 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.974 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 17 |
| Fraction csp3 | 0.3 |
| Ilogp | 3.82 |
| Xlogp3 | 4.05 |
| Wlogp | 4.9 |
| Mlogp | 4.62 |
| Silicos-it log p | 4.82 |
| Consensus log p | 4.44 |
| Esol log s | -4.92 |
| Esol solubility (mg/ml) | 0.00468 |
| Esol solubility (mol/l) | 0.000012 |
| Esol class | Moderately |
| Ali log s | -4.74 |
| Ali solubility (mg/ml) | 0.00714 |
| Ali solubility (mol/l) | 0.0000182 |
| Ali class | Moderately |
| Silicos-it logsw | -7.39 |
| Silicos-it solubility (mg/ml) | 0.0000159 |
| Silicos-it solubility (mol/l) | 4.06E-08 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.81 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.91 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.603 |
| Logd | 4.3 |
| Logp | 5.02 |
| F (20%) | 0.001 |
| F (30%) | 0.001 |
| Mdck | 1.59E-05 |
| Ppb | 0.9628 |
| Vdss | 0.878 |
| Fu | 0.0231 |
| Cyp1a2-inh | 0.273 |
| Cyp1a2-sub | 0.201 |
| Cyp2c19-inh | 0.912 |
| Cyp2c19-sub | 0.799 |
| Cl | 1.829 |
| T12 | 0.049 |
| H-ht | 0.837 |
| Dili | 0.862 |
| Roa | 0.381 |
| Fdamdd | 0.953 |
| Skinsen | 0.083 |
| Ec | 0.003 |
| Ei | 0.012 |
| Respiratory | 0.757 |
| Bcf | 1.756 |
| Igc50 | 4.058 |
| Lc50 | 5.53 |
| Lc50dm | 6.622 |
| Nr-ar | 0.013 |
| Nr-ar-lbd | 0.034 |
| Nr-ahr | 0.807 |
| Nr-aromatase | 0.828 |
| Nr-er | 0.414 |
| Nr-er-lbd | 0.006 |
| Nr-ppar-gamma | 0.452 |
| Sr-are | 0.802 |
| Sr-atad5 | 0.036 |
| Sr-hse | 0.095 |
| Sr-mmp | 0.701 |
| Sr-p53 | 0.913 |
| Vol | 385.213 |
| Dense | 1.015 |
| Flex | 0.185 |
| Nstereo | 2 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | 1 |
| Toxicophores | 2 |
| Qed | 0.724 |
| Synth | 3.433 |
| Fsp3 | 0.304 |
| Mce-18 | 110.933 |
| Natural product-likeness | -1.175 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 1 |
| Gsk | Rejected |
| Goldentriangle | Accepted |